A5036586629- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Medication Adherence and Compliance
- Ovarian cancer diagnosis and treatment
- Urologic and reproductive health conditions
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Pharmaceutical Practices and Patient Outcomes
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Glycosylation and Glycoproteins Research
- Genital Health and Disease
- Testicular diseases and treatments
- DNA Repair Mechanisms
- Lung Cancer Research Studies
Hospital Israelita Albert Einstein
2016-2025
Hospital São Paulo
2004-2021
Spanish Oncology Genitourinary Group
2006
Memorial Sloan Kettering Cancer Center
2002-2004
Cornell University
2002
To develop a pretreatment prognostic model for survival of patients with progressive metastatic prostate cancer after castration using parameters that are measured during routine clinical management.Pretreatment and biochemical determinants from 409 enrolled onto 19 consecutive therapeutic protocols June 1989 through January 2000 were evaluated. The factors selected age, Karnofsky performance status (KPS), hemoglobin (HGB), prostate-specific antigen (PSA), lactate dehydrogenase (LDH),...
Importance The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA AAP. Objective To investigate the association of ADT AAP, AAP health-related quality life (HRQOL) in CSPC trial. Design, Setting, Participants clinical comprised 128 who were (1:1:1) to 1 arms from October 16, 2017,...
PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. METHODS We conducted a multicenter retrospective analysis involving 12 sites. collected genomic clinical data from 123 2-altered who were treated inhibitors. The...
Os autores revisaram amplamente a literatura em relação aos fatores psiquiátricos envolvendo o câncer de mama. Dentro da linha raciocínio mestra dos tratamentos cirúrgico e oncológico dessas pacientes, ressalta-se seu impacto sobre saúde mental. Aspectos como possibilidades cirúrgicas, imagem corporal auto-estima sexualidade, sistêmicos conseqüências físicas, tais fadiga, náuseas vômitos, foram discutidos. As diferenças entre os grupos etários submetidos ao tratamento também relevadas,...
Abstract Purpose Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments still challenging. This paper presents update expert panel consensus from Latin American Cooperative Oncology Group Cancer on advanced renal management in Brazil. Methods A 34 oncologists experts discussed voted best options for managing Brazil, including...
Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free alternatives CSPC.
Abstract BACKGROUND Preclinical and clinical data have suggested that high‐dose calcitriol (1,25‐dihydroxycholecalciferol) has activity against prostate carcinoma. Pulse‐dosed dexamethasone may maximize tolerability efficacy. The authors examined the toxicity of pulse‐dosed with zoledronate addition at time disease progression. METHODS Patients progressive carcinoma were eligible for current study. In cohorts 3–6 patients, was administered 3 consecutive days per week, starting a dose 4 μg...
Purpose: Ultrasound-magnetic resonance imaging (US-MRI) fusion biopsy (FB) improves the detection of clinically significant prostate cancer (PCa). We aimed to compare Gleason upgrading (GU) rates and concordance scores in versus final pathology after surgery patients who underwent transrectal ultrasound (TRUS) systematic random biopsies (SRB) US-MRI FB for PCa. Materials Methods: A retrospective analysis data that were collected prospectively from January 2011 June 2016 subsequent radical...
Abstract Purpose: To investigate the safety and feasibility of rapid androgen cycling for men with progressive prostate cancer. Experimental Design: Schedule 1 included a 4-week induction depletion, followed by treatment cycles monthly gonadotropin-releasing hormone agonist, testosterone on days to 7, an estrogen patch 8 21. 2 12-week depletion agonist testosterone, but no estrogens patients prostate-specific antigen (PSA) nadir <1 ng/mL after induction. The primary end point was...
Testosterone suppression is the standard treatment for advanced prostate cancer, and it associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, increased cardiovascular risk. We hypothesized abiraterone acetate prednisone (AAP) apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.Phase II, open-label, randomized, efficacy trial plus Androgen...
Objective To determine the overall survival of patients with advanced pancreatic cancer and evaluate factors that impact prognosis in a private center.Methods Data from Hospital Cancer Registry at Israelita Albert Einstein were retrospectively collected. The enrolled had metastatic diagnosis or earlier staging subsequent recurrence. Cases neuroendocrine tumors excluded.Results A total 65 evaluated, including 63 adenocarcinoma. median for all stages was 20.7 months (95%CI: 15.6-25.7), while...
Prostate cancer is the second most common and fi fth leading cause of deaths. In Brazil, it likewise among men, only to non-melanoma skin cancers. The aim this consensus align different opinions interpretations medical literature in a practical patient-oriented approach. rst Brazilian Consensus on Treatment Advanced Cancer was published 2017, with goal reducing heterogeneity therapeutic conduct patients metastatic prostate cancer. We acknowledge that Brazil incorporation technologies big...
Prostate cancer still represents a major cause of morbidity, and about 20% men with the disease are diagnosed or will progress to advanced stage without possibility curative treatment. Despite recent advances in scientific technological knowledge availability new therapies, there is considerable heterogeneity therapeutic approaches for metastatic prostate cancer.This article presents summary I Brazilian Consensus on Advanced Cancer, conducted by Society Urology Clinical Oncology.Experts were...
The biochemical recurrence after local treatment for prostate cancer is an often challenging condition of clinical management. aim this report to demonstrate the importance association various imaging methods in identification and subsequent accurate percutaneous biopsy patients with cancer, especially unusual sites. An 86 years old male recurrence, during radiological investigation a PET-MRI was noted presence asymmetry vas deferens PSMA- 68Ga uptaken, suggesting recurrence. A fusion...
100 Background: Two PARP inhibitors (olaparib, rucaparib) are now FDA approved for mCRPC patients with mutations in BRCA1/2, but the relative efficacy of inhibition BRCA1- vs BRCA2-altered is understudied. Methods: We conducted a multi-center retrospective analysis involving 11 academic sites. collected genomic and clinical data from 123 BRCA1/2-altered receiving inhibitor treatment. The primary endpoint was PSA50 response rate (≥50% decline PSA level). Secondary endpoints were PFS...
Germ-cell tumors (GCTs) are the most common malignancy in young men. There is a paucity of data on GCTs developing countries. LACOG 0515 study aimed to evaluate clinical characteristics and treatment outcomes patients with from Brazilian cancer centers.This retrospective cohort evaluating male diagnosed 2000 2018 13 hospitals. We described baseline characteristics, progression-free survival (PFS), overall (OS).A total 1232 were included, median age 30 years. Histology was seminoma 47.1%...